Spero Therapeutics
SPRO
79 hedge funds and large institutions have $15.5M invested in Spero Therapeutics in 2022 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 20 increasing their positions, 22 reducing their positions, and 35 closing their positions.
1.23% more ownership
Funds ownership: 62.63% → 63.86% (+1.2%)
6% more call options, than puts
Call options by funds: $36K | Put options by funds: $34K
9% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 22
21% less funds holding
Funds holding: 100 → 79 (-21)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
54% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 35
91% less capital invested
Capital invested by funds: $180M → $15.5M (-$164M)
Top Buyers
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$4.37M |
| 2 |
Renaissance Technologies
New York
|
+$2.41M |
| 3 |
D.E. Shaw & Co
New York
|
+$1.83M |
| 4 |
Two Sigma Investments
New York
|
+$1.04M |
| 5 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
+$838K |
Top Sellers
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$5.1M |
| 2 |
AIC
AWM Investment Company
New York
|
-$3.24M |
| 3 |
BlackRock
New York
|
-$3.21M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.71M |
| 5 |
State Street
Boston,
Massachusetts
|
-$1.15M |
SPRO Hedge Fund Activity: Q2 2022 in Review
79 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q2 2022, worth a combined $15.5M — down 91% from $180M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of SPRO and 16 opened new positions — a net loss of 19 holders — while 22 trimmed existing stakes and 20 added.
The largest buyer was BVF Inc, adding an estimated $4.37M. The largest seller was Ameriprise, exiting entirely with an estimated $5.1M sold.
- 79 institutional investors held Spero Therapeutics (SPRO) as of Q2 2022, down from 100 in Q1 2022.
- Funds reported $15.5M of Spero Therapeutics stock for Q2 2022, down 91% quarter-over-quarter.
- 16 funds opened new Spero Therapeutics positions in Q2 2022 and 35 closed out, a net change of -19 holders.
- The largest Spero Therapeutics buyer in Q2 2022 was BVF Inc, an estimated $4.37M added.
- The largest Spero Therapeutics seller in Q2 2022 was Ameriprise, an estimated $5.1M sold.
Based on aggregated 13F filings for Q2 2022.